AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology.
The last earnings update was 29 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
AmpliPhi Biosciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
AmpliPhi Biosciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
AmpliPhi Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
AmpliPhi Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
AmpliPhi Biosciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
AmpliPhi Biosciences's finances.
The net worth of a company is the difference between its assets and liabilities.
AmpliPhi Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
AmpliPhi Biosciences's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
AmpliPhi Biosciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
AmpliPhi Biosciences has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Paul C. Grint, M.D., has been the Chief Executive Officer of AmpliPhi Biosciences Corporation since May 31, 2017. Dr. Grint served as the Chief Executive Officer and President of Regulus Therapeutics Inc. since June 1, 2015 until May 4, 2017 and served as its Chief Medical Officer from June 16, 2014 to June 1, 2015. Dr. Grint has over two decades of experience in biologics and small molecule development, including the successful commercialization of products in oncology, anti-infectives and immunology. Prior to Regulus, Dr. Grint served as the President at Cerexa, Inc. and was responsible for the oversight of Anti-Infective product development. Prior to joining Cerexa, he served as Senior Vice President at Forest Research Institute, Inc. He served as the Chief Medical Officer and Head of Development at Kalypsys, Inc. He served as Chief Medical Officer and Senior Vice President of Zephyr Sciences, Inc. Prior to joining Zephyr, Dr. Grint served as Vice President and Head of Clinical Research and Development of Pfizer Inc. in La Jolla. He served in executive level positions at Pfizer Inc., IDEC Pharmaceuticals Corporation and Schering-Plough Corporation. He served as Chief Medical Officer and Senior Vice President of Medical and Clinical Research and Development at Biogen Inc. since January 2001. Prior to joining Biogen, Dr. Grint was employed with Schering-Plough Research Institute from 1992 to 2000 and served as its Vice President of Clinical Immunology and Biotechnology. He has been a Director at AmpliPhi Biosciences Corporation since November 2015. He has been a Director of Amplyx Pharmaceuticals, Inc. since May 24, 2016. He serves as a Member of Advisory Board at CovX Research LLC. He served as a Director at Numira Biosciences, Inc. He served as a Director of Regulus Therapeutics Inc. since June 1, 2015 until May 4, 2017. He served as Member of Scientific Advisory Board at MultiCell Technologies, Inc. He served as a Member of clinical Advisory Board of Tobira Therapeutics, Inc. Dr. Grint served as a Director of Illumina Inc. from April 12, 2005 to May 29, 2013. He serves as Chairman of the Advisory Council of the Keck Graduate Institute. He served as the Chairman of the Biotechnology Therapy Team at St. Bartholomew's Hospital in London. He served as an Honorary Lecturer in the Department of Virology at St. Bartholomew's Hospital in London. Dr. Grint is a Fellow of the Royal College of Pathologists, a member of numerous professional and medical societies and the author or co-author of over fifty scientific publications. Dr. Grint received his Medical Degree from the University of London, St. Bartholomew's Hospital Medical College in London, U.K. He has a B.S. in Medical Science from Barts & The London School of Medicine & Dentistry, Queen Mary University of London.
Paul's compensation has been consistent with company performance over the past year.
Paul's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the AmpliPhi Biosciences management team is less than 2 years, this suggests a new team.
CEO & Director
Senior VP & CFO
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the AmpliPhi Biosciences board of directors is about average.
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections. AmpliPhi Biosciences Corporation has a collaboration agreement and a license agreement with the University of Leicester; and a collaboration agreement with the Western Sydney Local Health District and the Westmead Institute for Medical Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.